“Our management team and Board of Directors strongly believe that
NantKwest’s growth prospects and long-term strategy are not reflected in
the company’s current stock price,” said Dr.
The stock purchases may be made from time to time in the open market or
in privately negotiated transactions, in compliance with applicable
state and federal securities laws. The timing and amounts of any
purchases will be based on market conditions and other factors,
including price, regulatory requirements and other corporate
considerations, as determined by NantKwest’s management team. The
program does not require the purchase of any minimum number of shares
and may be suspended, modified or discontinued at any time without prior
NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
The aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe
Jen Hodson, 562-397-3639